Business Context and Reporting Period
This Form 8-K filing by Pavmed Inc. covers events occurring on January 23, 2025, and January 24, 2025. The company is incorporated in Delaware and its securities trade on The Nasdaq Stock Market LLC under the symbols PAVM (Common Stock) and PAVMZ (Series Z Warrants).
Key Financial Metrics and Capital Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. However, it details a specific capital transaction:
- Debt-to-Equity Conversion: On January 24, 2025, the company sold 2,653 shares of Series C Convertible Preferred Stock.
- Transaction Value: The purchase price was approximately $2.653 million.
- Payment Method: The purchase price was satisfied entirely through the cancellation of unsecured debt obligations owed by the company.
- Dilution Potential:
- At the voluntary conversion price of $1.068 per share, issuance would be approximately 2,484,082 shares.
- At the floor price of $0.2136 per share, issuance could reach approximately 12,420,412 shares.
Material Changes and Listing Status
Nasdaq Non-Compliance Notice: On January 23, 2025, Pavmed received notice from Nasdaq that its common stock closing bid price had been below the minimum requirement of $1.00 per share for 30 consecutive business days (through January 22, 2025), violating Listing Rule 5550(a)(2).
- Compliance Period: The company has been granted 180 calendar days (until July 22, 2025) to regain compliance.
- Requirement: The closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- Delisting Risk: If compliance is not achieved within the initial 180 days, the company may be eligible for an additional 180-day period. Failure to cure the deficiency thereafter may result in delisting.
- Current Status: Trading of PAVM and PAVMZ continues uninterrupted.
Outlook, Risks, and Management Commentary
Management Intent: The company intends to consider all available options to regain compliance with Nasdaq listing standards.
Risks and Contingencies:
- Delisting Risk: Continued failure to maintain the $1.00 minimum bid price could lead to the delisting of the company's securities.
- Dilution Risk: The issuance of Series C Preferred Stock introduces potential significant dilution to common shareholders, particularly if conversion occurs at the floor price.
- Liquidity: The transaction indicates the company utilized equity issuance to extinguish debt, suggesting ongoing liquidity management efforts.
Key Facts for Investor Verification
- Verify the current trading price of PAVM to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Review the terms of the Series C Convertible Preferred Stock (referenced in the November 21, 2024, 8-K) to understand specific conversion triggers and dividend rights.
- Monitor future filings for updates on the company's plan to regain Nasdaq compliance or any additional debt-to-equity conversions.
- Confirm the total amount of unsecured debt cancelled in the January 24 transaction to understand the impact on the company's balance sheet liabilities.